Core Insights - Accolade partners with Kindbody to enhance women's health, fertility, and family-building services for its customers, providing comprehensive support backed by a cost savings performance guarantee [1][4][5] Group 1: Partnership Overview - Kindbody is a technology-driven fertility clinic network that will join Accolade's Trusted Partner Ecosystem, aiming to provide integrated support throughout the fertility journey [1][2] - The partnership addresses the fragmented nature of fertility services in the U.S., where approximately one in six couples face infertility challenges [1][2] Group 2: Kindbody's Service Model - Kindbody offers a full continuum of reproductive health services, including fertility assessments, genetic testing, IVF, and support for donor, surrogacy, and adoption services [3] - The company provides a unique model by being both a family-building benefits provider and a direct care provider, utilizing a mix of owned clinics and partner clinics nationwide [2][3] Group 3: Benefits of the Partnership - Joint customers will benefit from integrations that promote awareness of Kindbody's services, enhancing access to fertility care without additional costs [4] - Kindbody's performance guarantee caps the average cost per member at a significant discount compared to industry averages, ensuring high-quality services at affordable rates [5] Group 4: Accolade's Ecosystem - Accolade's Trusted Partner Ecosystem includes 16 partners across 11 categories, providing a streamlined approach for employers to access various health benefits solutions [6] - The ecosystem aims to improve engagement with partner solutions, leading to better health outcomes and value for employers [6] Group 5: Company Backgrounds - Accolade is a personalized healthcare company focused on delivering exceptional healthcare experiences, combining virtual primary care, mental health, and expert medical opinions [7] - Kindbody serves as a leading national fertility clinic network, covering nearly 2.7 million lives through partnerships with 132 employers and offering a seamless, integrated experience [8]

Accolade (ACCD) closed the last trading session at $11.88, gaining 5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.07 indicates a 26.9% upside potential.The average comprises 14 short-term price targets ranging from a low of $12 to a high of $19, with a standard deviation of $2.06. While the lowest estimate indicates an increase of 1% from the current price level, the most o ...

One stock that might be an intriguing choice for investors right now is Accolade, Inc. (ACCD) . This is because this security in the Technology Services space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Technolo ...

andreswd Overview My recommendation for Accolade (NASDAQ:ACCD) is a buy rating, as I remain convicted that ACCD can grow 20% in FY25, driven by a strong core demand, health care plan strategy, GLP-1, and elevated demand for expert medical opinion. Note that I previously rated buy rating for ACCD as I expected ACCD to continue executing as guided and growing the business as I expected. As ACCD executes, valuation should re-rate to historical levels. Indeed, I believe the market recognized that valuation was ...

Accolade, Inc. (NASDAQ:ACCD) Q3 2024 Earnings Call Transcript January 8, 2024 4:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Conference Call Participants Ryan Daniels - Blair Craig Hettenbach - Morgan Stanley Ryan MacDonald - Needham Jailendra Singh - Truist Stan Berenshteyn - Wells Fargo Jessica Tassan - Piper Sandler Richard Close - Canaccord Genuity Allen Lutz - Bank of America Stephanie Davis - Barclays Jenny Shen - BTIG Jack Wallace - Guggenheim Partners O ...

January 2024 NASDAQ: ACCD ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ FORM 10-Q ______________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39348 ACCOLADE, INC. (Exa ...

Company Overview - Accolade, Inc. (NASDAQ: ACCD) is a Personalized Healthcare company that aims to provide exceptional healthcare experiences to millions of individuals and their families, enabling them to live healthier lives [2] - The company's solutions include virtual primary care, mental health services, expert medical opinions, and care navigation, all designed to address population health needs and improve healthcare outcomes while reducing costs [2] - Accolade has consistently achieved consumer satisfaction ratings exceeding 90% [2] Upcoming Events - Accolade will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2024, at 7:30 am PT [1] - The company will also participate in the 26th Annual Needham Growth Conference in New York on January 18, 2024, at 3:00 pm ET [1] - A webcast of these events will be available on the company's investor relations website, with a replay accessible for 90 days [1]

Accolade, Inc. (NASDAQ:ACCD) Q2 2024 Earnings Conference Call October 4, 2023 4:30 PM ET Company Participants Todd Friedman - Senior Vice President, Investor Relations Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Executive Vice President, Care Delivery and Chief Health Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Jessica Tassan - Piper Sandler Jailendra Singh - Truist Securities Jared Haase - William Blair Glen Santangelo - Jefferie ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39348 ACCOLADE, INC. (Exact name of registrant as specified in its charter) Delaware 01-0969591 (State or Other Juri sdiction of (I.R.S. ...